This article highlights the major studies of perioperative beta-blockade to prevent cardiac complications and identify which patients may benefi t most from this therapy.
C ardiac complications (cardiac death, nonfatal myocardial infarction, and nonfatal cardiac arrest) signifi cantly contribute to the morbidity and mortality that can occur during the perioperative period in patients undergoing major noncardiac surgeries. In-hospital mortality approaches 17% for patients that experience a perioperative myocardial infarction, 1 whereas those who survive to hospital discharge are at increased risk of cardiovascular death and nonfatal myocardial infarction 6 months postoperatively. 2 Mortality associated with perioperative cardiac arrest is 65%. Those that experience nonfatal cardiac arrest are at increased risk of cardiac death 5 years postoperatively.
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PATHOPHYSIOLOGY OF PERIOPERATIVE MYOCARDIAL INFARCTION
Major surgery can be likened to an extreme stress test. In the setting of surgical trauma, general anesthesia, intubation and extubation, fasting, hypothermia, and pain, the body produces excess levels of catecholamines and cortisol. This in turn results in increases in heart rate, blood pressure, and coronary artery shear stress, which can trigger plaque fi ssuring, acute coronary thrombosis, and signifi cantly increased cardiac oxygen demand. 4 Increased oxygen demand can precipitate perioperative myocardial ischemia, which has been strongly linked with the occurrence of perioperative myocardial infarction. 5 Ongoing research in this area aims to identify which underlying mechanism (plaque fi ssure/coronary thrombosis vs myocardial ischemia) may be the greatest contributor to the development of perioperative myocardial infarction in the hopes that prevention or attenuation can signifi cantly reduce the incidence of these perioperative cardiac complications.
RISK ASSESSMENT
Pioneering work from the 1970s and 1980s 6, 7 identifi ed various risk factors associated with the development of cardiac complications and allowed the clinician to stratify patients according to risk for developing cardiac complications after noncardiac surgery. Given advancements in the modern practice of surgery, anesthesia, and postoperative care, Lee et al 8 developed a revised index referred to as the Revised Cardiac Risk Index for prediction of risk of cardiac complications following major noncardiac surgery. They observed 2893 patients undergoing elective major noncardiac procedures-the majority of which (66%) were orthopedic or high-risk vascular procedures-to identify 6 independent predictors of major cardiac complications, which were then validated among a cohort of 1422 patients. The risk of cardiac complications increased as the number of risk factors present increased (Table 1) .
In addition to identifying risk factors present for any given patient, it is also important to take into account the risk associated with the surgical procedure to be performed ( 
BETA-BLOCKER THERAPY
Numerous perioperative pharmacological therapies have been studied to prevent the occurrence of cardiac complications in patients undergoing noncardiac surgery. The most extensively studied agents have been cardioselective (␤1) beta adrenergic receptor antagonists. Because one of the underlying contributors to cardiac complications is the high stress state and corresponding increase in sympathetic activity that occurs during and following surgery, investigators postulated that attenuating this high sympathetic output would result in a signifi cant decrease in the mortality and morbidity associated with perioperative cardiac complications.
Initial studies produced promising results that supported the administration of ␤1-antagonists in high-risk patients undergoing major noncardiac surgery. The fi rst of these trials was a double-blinded, randomized controlled trial comparing the effects of atenolol vs placebo in 200 patients with or at risk for coronary artery disease undergoing elective major noncardiac surgery. 11 Overall mortality was signifi cantly lower in the atenolol group at all points A number of trials have investigated the possible benefi t of beta-blockade in various other patient populations that have produced discordant results as compared to the 2 trials mentioned above. The fi rst of these is the POBBLE trial, which compared metoprolol to placebo in 103 "lower-risk" patients undergoing infrarenal vascular surgery. 13 The investigators found no difference in the rates of 30-day cardiovascular events with metoprolol (34% vs 32%, aRR 0.87) but noted a signifi cant reduction in the time from operation to discharge in the metoprolol arm (10 vs 12 days, PϽ.02).
The DiPoM trial compared extended release metoprolol to placebo in type II diabetics scheduled to undergo major noncardiac surgery.
14 No signifi cant differences were noted in any of the primary or secondary endpoints. Short duration of beta-blocking therapy (average of 4.6 days) as well as the administration of a fi xed dose of extended release metoprolol (ie lack of titration to heart rate) were both signifi cant methodological fl aws of the trial.
The MaVS trial randomized 496 patients undergoing elective vascular surgery to metoprolol or placebo. 15 No significant difference was noted in the rates of primary outcome events (nonfatal myocardial infarction, unstable angina, new congestive heart failure, new atrial/ventricular dysrhythmia requiring treatment, or cardiac death) between groups at 30 days (10.2% vs 12.0%; Pϭ.57) or 6 months (Pϭ.81). However, signifi cantly more patients in the metoprolol arm experienced intraoperative hypotension and bradycardia requiring treatment.
The largest trial to date addressing the question of betablockade to reduce the incidence of cardiac complications in at-risk patients undergoing noncardiac surgery is the POISE trial. In this trial, 8351 patients with or at risk for coronary artery disease undergoing major noncardiac surgery (~40% vascular) were randomly assigned to treatment with either extended release metoprolol at 100 mg once daily vs placebo. 16 Fewer patients in the metoprolol group than the placebo group reached the primary endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal cardiac arrest) at 30 days (5.8% vs 6.9%, Pϭ.04). The reduction in the rate of myocardial infarction (4.2% vs 5.7%, Pϭ.0017) was responsible for the overall benefi t noted with metoprolol treatment. However, signifi cantly more deaths occurred in the metoprolol group (3.1% vs 2.3%; Pϭ.0317) due to a higher incidence of stroke (1.0% vs 0.5%; Pϭ.0053). A major fl aw in trial design is the administration of extended release metoprolol, which cannot be titrated to heart rate given its signifi cantly long half-life. It should be noted that a greater proportion of patients in the metoprolol group experienced signifi cant hypotension (15% vs 9.7%) and bradycardia (6.6% vs 2.4%). It is plausible that the excess episodes of hypotension are responsible for the increased rates of stroke noted in POISE.
DECREASE-IV is the most recently conducted trial. It used a 2ϫ2 factorial design that randomized 1066 intermediaterisk patients undergoing vascular surgery to receive bisoprolol (titrated to perioperative heart rate 50-70 beats per minute), fl uvastatin, a combination of the 2, or double placebo. 17 Patients randomized to bisoprolol had a signifi cantly lower incidence of 30-day cardiac death and nonfatal myocardial infarction (2.1% vs 6.0%; Pϭ.002).
No difference was noted between bisoprolol and placebo in the incidence of beta-blocker related safety endpoint (stroke, heart failure, clinically significant bradycardia, or hypotension). Lack of blinding and early termination due to slow enrollment are noteworthy limitations of this trial.
Since the publication of POISE and DECREASE-IV, the American College of Cardiology (ACC) and the American Heart Association (AHA) issued a focused update on beta blockade 18 to the guidelines on perioperative care for noncardiac surgery. The guidelines recommend beta blocker therapy titrated to heart rate and blood pressure as reasonable in patients undergoing vascular or intermediate risk surgery who are identifi ed as high risk defi ned by the presence of Ͼ1 clinical risk factor. Given the relationship between bradycardia or hypotension and morbidity or mortality found in POISE, a new recommendation is that routine administration of high-dose beta blockers in the absence of dose titration is not useful and may be harmful and the committee advises that any beta-blocker protocol should be designed to avoid hemodynamic instability.
RECOMMENDATIONS
Given the confl icting results of the available evidence, which patients should receive beta-blockers and how should they be administered? As noted above, the ACC and AHA recommend beta-blockers for patients who carry a high cardiac risk. The data are less clear when choosing which beta-blocker to use; the clinician should take into account the differences in pharmacology of the various drugs. A cardioselective agent (metoprolol, atenolol, or bisoprolol) titrated to a heart rate between 60 and 80 beats per minute is recommended. Given the current data, it is possible that beta-■ pharmacology update blockers with a longer half-life (atenolol and bisoprolol) may be more effective than shorter acting agents (metoprolol). The POISE trial emphasizes the deleterious effects of sustained perioperative hypotension; therefore the use of extended release formulations of betablockers should be avoided in this patient population.
Of note, the thresholds for withholding treatment in POISE were a systolic blood pressure Ͻ100 mm Hg or heart rate Ͻ45 beats per minute. Protocols should use more conservative parameters with clear guidelines that defi ne when to reduce the dose or hold therapy altogether to avoid signifi cant hypotension or bradycardia.
Given the considerable variability between beta-blockade protocols, the current literature does not elucidate the optimal timing of initiation of these agents nor does it delineate an appropriate duration of therapy. If possible, earlier initiation (ie, weeks vs days or hours) would be of greater benefi t, as it will allow the clinician adequate time to stabilize the patient's heart rate and blood pressure preoperatively.
Duration of therapy is up for debate. The majority of protocols have continued beta-blockade for 7 days after surgery, but more recent trials have continued therapy for 30 days postoperatively. Given that sympathetic tone increases postoperatively and returns to baseline within 4 to 5 days, perioperative betablockade should be continued for at least 7 days in hemodynamically stable patients.
THE BOTTOM LINE
• Cardiac complications-such as perioperative myocaridal infarction, new onset congestive heart failure and cardiac arrest-occurring after noncardiac surgery greatly infl uence patient morbidity and mortality.
• The most recent ACC/AHA guidelines recommend that patients scheduled to undergo vascular or intermediate-risk surgery (eg, orthopedic surgery) with Ͼ1 clinical risk factor be treated with cardioselective beta-blocker therapy with the dose titrated to a heart rate between 60 and 80 beats per minute.
• Beta-blockers that have been prospectively studied include atenolol, bisoprolol, and metoprolol but there are currently no comparative trials of these agents. Extended release beta-blockers should be avoided in this patient population as they may increase the risk of sustained signifi cant perioperative hypotension.
• Perioperative beta-blockade should be initiated weeks prior to surgery to stabilize the patient's resting heart rate and blood pressure. Therapy should be continued for at least 7 days unless the patient develops signifi cant hypotension or bradycardia.
